Pyxis Oncology Inc
NASDAQ:PYXS
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
1.52
6.59
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Pyxis Oncology Inc
Total Liabilities
Pyxis Oncology Inc
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Pyxis Oncology Inc
NASDAQ:PYXS
|
Total Liabilities
$48m
|
CAGR 3-Years
131%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Abbvie Inc
NYSE:ABBV
|
Total Liabilities
$137.4B
|
CAGR 3-Years
1%
|
CAGR 5-Years
15%
|
CAGR 10-Years
19%
|
||
Gilead Sciences Inc
NASDAQ:GILD
|
Total Liabilities
$36.1B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
9%
|
||
Amgen Inc
NASDAQ:AMGN
|
Total Liabilities
$83.4B
|
CAGR 3-Years
14%
|
CAGR 5-Years
11%
|
CAGR 10-Years
6%
|
||
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Liabilities
$6.6B
|
CAGR 3-Years
29%
|
CAGR 5-Years
24%
|
CAGR 10-Years
18%
|
||
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Liabilities
$8.1B
|
CAGR 3-Years
8%
|
CAGR 5-Years
19%
|
CAGR 10-Years
21%
|
Pyxis Oncology Inc
Glance View
Pyxis Oncology, Inc. engages in the development of antibody therapeutics. The company is headquartered in Cambridge, Massachusetts and currently employs 56 full-time employees. The company went IPO on 2021-10-08. The firm has developed a portfolio of antibody drug conjugate (ADC), immuno-oncology (IO), product candidates, and monoclonal antibody (mAb), preclinical discovery programs that are developing as monotherapies and in combination with other therapies. Its pipeline includes PYX-106, PYX-102, PYX-201, PYX-202 and PYX-203. Its PYX-106 is an investigational, fully human IgG1 isotype Siglec-15 targeting antibody that is designed to block Siglec-15-mediated suppression of T-cell proliferation and function. PYX-102 is an investigational immune-therapeutic consisting of a ligand-blocking antibody which rescues KLRG1-mediated suppression of human CD8+ T cells. PYX-201 is an investigational ADC consisting of an immunoglobulin G1 (IgG1), anti-fibronectin Extradomain-B (EDB), mAb site-specifically conjugated to auristatin via a cathepsin B-cleavable linker.
See Also
What is Pyxis Oncology Inc's Total Liabilities?
Total Liabilities
48m
USD
Based on the financial report for Dec 31, 2023, Pyxis Oncology Inc's Total Liabilities amounts to 48m USD.
What is Pyxis Oncology Inc's Total Liabilities growth rate?
Total Liabilities CAGR 3Y
131%
Over the last year, the Total Liabilities growth was -5%. The average annual Total Liabilities growth rates for Pyxis Oncology Inc have been 131% over the past three years .